You just read:

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019

News provided by

Eiger BioPharmaceuticals, Inc.

Mar 25, 2019, 13:30 ET